

23. Liddle R. A. Cholecystokinin / R. A. Liddle // *Armu. Rev. Physiol.* 1997. Vol. 59. P. 221-242.

24. Mawe G. M. Innervation of the gallbladder structure neurochemical coding and physiological properties of guinea pig gallbladder ganglia / G. M. Mawe et al. // *Microsc. Res.Tech.* 1997. Vol. 39. N1. P. 1-13.

25. Sonode R. Control of gallbladder contractions by cholecystokinin through cholecystokinin-A receptors in vagal pathway and gallbladder in the dog / R. Sonode [et al.] // *Regul. Pept.* 1995. Vol. 60. N1. P. 33-46.

26. Xu . X. // *SonoAce-International.* — 10. — 2002. — . 3-9.

27. Kurjiak, S. Kupesic *Clinical application of 3D sonography* / Kurjiak, S. Kupesic // *NewYork — London, Parthenon Publ. Group.* — 2000. — . 235-241.

12.06.2013

616.37-002.2-02:616.366+616-056.52]-073.432.19.

I. V. Yakubovskaya

PECULIARITIES OF ETIOPATHOGENESIS, CLINIC AND DIAGNOSIS OF GALLBLADDER CHOLESTEROSIS (LITERATURE REVIEW)

Key words: cholesterosis, lipid exchange, cholesecretor function, cholelithiasis, sonography.

The data about etiology, pathogenesis, clinical symptoms, classification, lipid exchanges of gallbladder cholesterosis are given. The interaction between liver cholesecretor dysfunction, gallbladder cholesterosis and cholelithiasis are shown. The principal method of investigation for diagnosing various forms of gallbladder cholesterosis is US.

: 616.5-056.3-08-079.4

« »

• . . , . . „
 . . , . . „
 . . , . . „
 . . , . . „

• ,

() - - , [1-6].

() - -

« - - - - - ()

() [7-11].

()

[4, 6].

1 (60),

()

« », 2

(46

),

40

66 ;

18 59

[4, 5, 10, 11].

« »

« ».

(. .)

« »

200

[4, 8, 9, 11].

[1, 3, 4, 11].

()

« »

[3, 5, 9, 11].

[2, 10].

(CD3+),

(CD4+

[1-5].

CD4/CD8 () ;

(CD8+)

(CD22+)

(.1).

(±)

		(±)		
		1- (= 60)	2- (= 46)	
CD3+ % / /	69,2±2,3 1,3±0,04	50,4±2,1* 0,81±0,03**	51,2±2,2* 0,82±0,0 **	>0,1 >0,1
+ % / /	45,8±1,6 0,86±0,03	35,1±1,8** 0,56±0,03**	35,3±1,7** 0,56±0,03**	>0,1 >0,1
CD8+ % / /	22,9±1,1 0,43±0,02	21,8±1,2 0,35±0,02	22,3±1,3 0,36±0,02	>0,1 >0,1
	2,0±0,002	1,61±0,02**	1,58±0,02**	>0,1
CD22+ % / /	22,1±1,2 0,42±0,02	23,6±1,3 0,38±0,02	23,8±1,4 0,38±0,02	>0,1 >0,1
%	69,5±2,5	40,6±2,1***	41,1±2,2***	>0,1

: 1 2

(±)

		(±)		
		1- (= 60)	2- (= 46)	
CD3+ % / +	69,2±2,3 1,3±0,04	69,4±2,2 1,28±0,04	54,2±2,1* 0,92±0,036**	<0,05 <0,01
CD8+ % / +	45,8±1,6 0,86±0,03	45,2±1,5 0,84±0,03	38,1±1,6 0,65±0,03**	<0,05 <0,01
CD4/CD8	2,0±0,002	1,98±0,003	1,8±0,02*	>0,05 >0,05
CD22+ % / %	22,1±1,2 0,42±0,02	22,5±1,3 0,42±0,02	23,8±1,4 0,39±0,02	>0,05 >0,01
	69,5±2,5	66,8±2,3	51,1±2,5*	<0,05

», 1,6 (<0,01) - (<0,001) (2).
 / (CD4+) -
 CD4/CD8- ^ [1, 2, 3, 4]. 1,25 (<0,05), - 1,35 (<0,01) [5, 8, 10].
 « »
 (. 3).
 « » (. 2). (±), (. . .)

	(= 20)	(= 60)	
CD4+ (- / - CD4/CD8)	90 ± 0,1	250 ± 0,18*	180 ± 0,12**
	90 ± 0,5	290 ± 0,20*	135 ± 0,19**
(D3+ -)	90 ± 0,4	95 ± 0,21	90 ± 0,01

CD3+- < 0,05; ** - < 0,05; *** - < 0,05.
 1,3
 (<0,05) 1,4
 (<0,01). CD4+ « - »
 1,2 (<0,05) 1,32 (<0,01), [7, 9, 10, 11].
 1,7 - 1,68 (<0,001) (>0,1).
 (<0,001) (1). « - »

[3, 6, 9].

CD4+ (4/ 8)

[1, 5, 7].

« »

»

[1, 3, 4, 6, 8].

Th/Ts

[2, 6, 8].

»

« »
[3, 4, 6, 9, 10, 11].

1. // - 2008 . - 365 .
2. / . - 2006. - 772-779.
3. // : , 2006. - 528 .
4.) . - : . - 2000. - 806 .
5. // . - 2012. - 922 .
6. / . - 2009. - 92 .

7. / - 2006. - 482 .
8. / , 2003. - 112 .
9. / : « » - 2002. - 624 .
10. (. - : « » - 2011. - 550 .
11. / . J. - 2008 . - 37 .

07.05.2013

: 616.5-056.3-08-079.4_

M. . ShulyaK, . V. Yurkina, A. G. Kuznetsov, T. N. Bondarenko, E. V. Kravchenko

INFLUENCE OF PREPARATION «IMMODIN» ON INDEXES OF CELLULAR IMMUNITY AND CIRCULATORY IMMUNE COMPLEXES IN PATIENTS WITH POLIPOUS RHINOSINUSITIS AND ALL-YEAR ALLERGIC RHINITIS

Key words: nasal polypus, sinusitis, all-year allergic rhinitis, Immodin, circulatory immune complexes.

Clinical application of preparation «Immodin» improved both subjective and objective symptoms in patients with nasal polypus, sinusitis and all-year allergic rhinitis, and liquidation or diminishing of signs of intensity of chronic inflammatory process. Findings allowed to consider including preparation «Immodin» in the program of medical measures for patients with nasal polypus, sinusitis and all-year allergic rhinitis pathogenetic grounded and clinically perspective.